are they going to stop selling semaglutide Market Size, Share, Opportunity, Growth, 2034 Semaglutide Shortage Ends: Compounded Versions

Subgroup analysis The subgroup analysis by Malkin S J P et al

Highlights GLP-1 medicines reduce fat and liver mass more rapidly than skeletal muscle (SKM) Running performance is maintained or improved in mice on GLP-1 medicine GLP-1 medicine modifies the SKM proteome despite similar weight loss as calorie restriction Patients on GLP-1 medicine slightly reduce SKM mass but largely maintain strength Summary The large decrease in body weight with glucagon-like peptide-1 (GLP-1) medicines raises concern about a loss of lean body mass (LBM) and skeletal muscle

Insulin resistance can also affect the balance of other hormones, such as leptin and ghrelin, which regulate appetite and satiety

We don't have head-to-head data against tirzepatide in a controlled trial